


Understanding what oncologists need

for their patients and their clinics

The current oncology pipeline: development and launch

Exceptional launch activity increases options for patients but requires a greater understanding of the impact on treatment pathways and patient segments for payers and clinicians.



These figures are estimates based on phase III completion dates. The actual number of launches will depend on successful trial completion and FDA approval. Products in phase II that could successfully move through launch are <u>not</u> included.

Key:



Targeted



Immuno-oncology



Chemotherapy



Vaccine



Oncolytic Virus



Other




Total Clinical Activity



The pipeline of oncology drugs in clinical development has expanded by

more than 60%








need to understand clinical benefits and patient outcomes



need to assess the therapies' place in the clinical pathway and treatment guidelines

What are patient's biggest concerns apart from survival when initiating a new treatment regime?





What services are most valuable to oncologists and their patients?



say the provision of education/support about the new drug



23%

ask for face to face nursing support to train/educate patients

% 98

oncologists were surveyed across the top 5 EU countries, to understand what they require to help them, and their patients get the most out of cancer care.

We understand that you navigate a complex environment when introducing a new cancer therapy to oncologists.

Discover how we can design a tailored approach to help you meet your goals.

- ✓ Market access strategic consultancy
- Research and insights generation
- ✓ MSL training and deployment
- ✓ Clinical nurse educators
- ✓ Pathway redesign
- Multichannel patient engagement programs

Reference: QuintilesIMS (2016) Oncology Survey, Exploring Need. Data on File.

1. IMS Health (2016) Global Oncology Trend Report: A Review of 2015 and Outlook to 2020.